CYP2C9 and acute myeloid leukemia: R-AML was also a significantly more potent inhibitor of CYP2C9 (Ki 12.11 μM/S-AML 21.45 μM) and CYP2C19 (Ki 5.97 μM/S-AML 7.22 μM.